摘要
新型抗肿瘤疗法大大提高了癌症的存活率; 然而,他们正在引入新形式的心肌病,这通常可以限制适当的癌症治疗。 因此,需要新的心脏保护疗法,以改善癌症患者的临床结果。 为了测试新的治疗策略,对化学疗法诱发的心肌病的适当实验模型的需求越来越多。 诱导的多能干细胞和人类胚胎干细胞(hESC)来源的心肌细胞可用作替代体外模型,用于研究化疗诱发型心肌病的机制。 在本综述中,我们讨论了使用iPS-和hESC衍生的心肌细胞来评估额外的药物靶点和预测化疗引起的心脏毒性。
关键词: 心脏干细胞,化疗诱导的心脏毒性,多能干细胞,临床前模型,心肌病,人类胚胎干细胞。
Current Drug Targets
Title:Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Volume: 18 Issue: 6
关键词: 心脏干细胞,化疗诱导的心脏毒性,多能干细胞,临床前模型,心肌病,人类胚胎干细胞。
摘要: Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC )-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.
Export Options
About this article
Cite this article as:
Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells, Current Drug Targets 2017; 18 (6) . https://dx.doi.org/10.2174/1389450117666160401125404
DOI https://dx.doi.org/10.2174/1389450117666160401125404 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ACE Inhibition Prevents Diastolic Ca2+ Overload and Loss of Myofilament Ca2+ Sensitivity after Myocardial Infarction
Current Molecular Medicine Cardiomyopathy of Pregnancy
Current Women`s Health Reviews The Spatial QRS-T Angle: Implications in Clinical Practice
Current Cardiology Reviews Role of Heme Oxygenase-1 in Cardiovascular Function
Current Pharmaceutical Design Chagas Disease Chemotherapy: What Do We Know So Far?
Current Pharmaceutical Design Hsp70 Protein Complexes as Drug Targets
Current Pharmaceutical Design Erythropoietin in Stroke Therapy: Friend or Foe
Current Medicinal Chemistry 20-Hydroxyeicosatetraenoic Acid is a Potential Therapeutic Target in Cardiovascular Diseases
Current Drug Metabolism Artificial Neural Networks in Cardiovascular Diseases and its Potential for Clinical Application in Molecular Imaging
Current Radiopharmaceuticals Pharmacology of Ivabradine and the Effect on Chronic Heart Failure
Current Topics in Medicinal Chemistry Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety?
Current Drug Safety Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Current Vascular Pharmacology Proteomics to Identify Novel Biomarkers and Therapeutic Targets in Cardiovascular Disease
Letters in Drug Design & Discovery MicroRNA Therapeutics for Cardiac Regeneration
Mini-Reviews in Medicinal Chemistry The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Withdrawal Notice: Therapeutic Options for Treatment of COVID-19: A Review from Repurposed Drugs to New Drug Targets
Current Drug Targets Fetal Risks of Maternal Diabetes
Current Women`s Health Reviews Molecular Basis of Antiretroviral Drugs-Associated Long-Term Toxicity: How Bad can Good Drugs Be?
Current Medicinal Chemistry - Anti-Infective Agents Dynamics of Toll-like Receptors Signaling in Skeletal Muscle Atrophy
Current Medicinal Chemistry